Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA Remote Record Review

The US FDA has concluded Remote Record Review of Shilpa Medicare Limited ('SML' or 'the Company'), Unit III, Advanced Analytical Characterization Laboratory situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations. The review was conducted during 15th to 18th Nov 2021.

The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing, Nitrosamine testing, Elemental Impurity testing, Extractable & Leachable testing, Glass Delamination testing etc.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 412.90 as compared to the previous close of Rs. 408.90. The total number of shares traded during the day was 2430 in over 325 trades.

The stock hit an intraday high of Rs. 414.00 and intraday low of 409.70. The net turnover during the day was Rs. 1000603.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 USFDA RemoteRecordReview